Clinical trials: Tamoxifen
Breast Neoplasms, Neoplasms, Hormone-dependent
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
The purpose of this study is to determine whether the first line combination hormonal therapy of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug…
- Trial name
- NCT00044291
- Testing
- atamestane, toremifene, letrozole
- Where
- 63 sites in United States, Canada and 2 more
- Volunteers
- 865 people
- Sponsor
- Intarcia Therapeutics
Breast Cancer
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
The researchers want to learn whether ZD1839 can improve the activity of tamoxifen, a drug that participants will receive for the treatment of the type of breast cancer being studied.
- Trial name
- NCT00206492
- Testing
- Iressa, Tamoxifen
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Baylor Breast Care Center
Alzheimer Disease
Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease
The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability…
- Trial name
- NCT00065767
- Testing
- Raloxifene
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Breast Cancer, Hormone Receptor Positive
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
This phase II trial studies the side effects of palbociclib when given together with fulvestrant or tamoxifen citrate in treating patients with hormone receptor positive breast cancer that has spread from where it started to…
- Trial name
- NCT02384239
- Testing
- Palbociclib, Tamoxifen, Fulvestrant
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
Breast Neoplasms, Neoplasms, Hormone-Dependent
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another…
- Trial name
- NCT00097344
- Testing
- Atamestane, Toremifene, Letrozole
- Where
- 104 sites in United States, Bulgaria and 3 more
- Volunteers
- 842 people
- Sponsor
- Intarcia Therapeutics
Menstruation Disturbances
Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users
The purpose of this study is to study whether a drug called tamoxifen can reduce vaginal bleeding in women who are using the Etonogestrel contraceptive implant.
- Trial name
- NCT02070692
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Oregon Health and Science University
Breast Cancer
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Trial to optimize neoadjuvant therapy for HER overexpression and co-expressing of hormone receptors(ER and/or PR) breast cancer (HEr2+/HR+).
- Trial name
- ADAPT; T-DM1 (NCT01745965)
- Testing
- T-DM1, Trastuzumab
- Where
- 2 sites in Germany
- Volunteers
- 380 people
- Sponsor
- Women's Cancer Study Group GmbH
Osteoporosis, Postmenopausal
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether…
- Trial name
- NCT00046137
- Testing
- teriparatide, raloxifene
- Where
- 13 sites in United States
- Sponsor
- Eli Lilly and Company
Breast Atypical Hyperplasia, Breast Carcinoma
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer.
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT06195306
- Testing
- Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters
- Where
- 3 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy of addition of everolimus to letrozole with LHRH agonist in premenopausal metastatic breast cancer patients who failed to tamoxifen treatment.
- Trial name
- LEO (NCT02344550)
- Testing
- Everolimus(afinitor), Letrozole, Leuprolide(Lorelin Depot)
- Where
- South Korea
- Volunteers
- 137 people
- Sponsor
- Asan Medical Center
Breast Cancer
Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen
This study is designed as a phase 1 dose escalation study followed by a randomised phase II study. The study will be performed in three different centres: Addenbrooke \& Cambridge university (Cambridge, UK), Netherlands Cancer…
- Trial name
- Poseidon (NCT02285179)
- Testing
- GDC-0032, Tamoxifen
- Where
- 14 sites in France, Netherlands and 2 more
- Volunteers
- 189 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002580
- Testing
- cyclophosphamide, fluorouracil, goserelin acetate
- Where
- 10 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Scottish Cancer Therapy Network
Metastatic Breast Cancer, Estrogen Receptor Positive Tumor
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women
Fulvestrant is an ER antagonist with no agonist effects, which binds, blocks and degrades the ER. Fulvestrant is comparable to third-generation aromatase inhibitors in terms of efficacy and tolerability for patients who have…
- Conditions
- Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal
- Trial name
- FLAG (NCT01266213)
- Testing
- Fulvestrant plus Goserelin, Anastrozole plus Goserelin, Goserelin
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Samsung Medical Center
Pain, Discomfort
TAmoxifen Versus LIdocaine Cream. A Randomized Clinical Trial for Reducing Pain and Discomfort During Mammography
This is a double-blind placebo-controlled randomized clinical trial to test the use of tamoxifen or lidocaine for diminishing the pain and discomfort while performing mammography, intending to include 450 patients distributed…
- Trial name
- TALI (NCT02801786)
- Testing
- Lidocaine, Tamoxifen
- Where
- Brazil
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Universidade Federal de Goias
Prostate Cancer, Adenocarcinoma of the Prostate
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01050842
- Testing
- bicalutamide, raloxifene, quality-of-life assessment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Breast Neoplasms, Tamoxifen
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer
This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast…
- Trial name
- MHSLabCorp1 (NCT00830973)
- Testing
- Poor Metabolism Status Follow Up Therapy Considerations, CYP2D6 Inhibiting Drugs
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Medco Health Solutions, Inc.
Xiao Chai Hu Tang, Irinotecan-induced Diarrhea
XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)
Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide…
- Trial name
- NCT06055179
- Testing
- Xiao Chai Hu Tang (XCHT), Irinotecan regimen, Raloxifene
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
X Linked Myotubular Myopathy
Tamoxifen Therapy for Myotubular Myopathy
This is a phase 1 / 2, randomized, double-blinded, single cross-over study, with a washout period between treatment regimens, to test the efficacy and safety of tamoxifen therapy to improve motor and respiratory function in males…
- Trial name
- TAM4MTM (NCT04915846)
- Testing
- ApoTamox 10mg
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 6 people
- Sponsor
- James Dowling
Metastatic Invasive Breast Cancer, Resistant Breast Cancer
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
The goal of this clinical trial is to learn if neratinib, an FDA-approved oral pan-HER2/3/4 inhibitor, improves disease control for participants with metastatic endocrine-resistant ER+/HER2-negative breast cancer.
- Conditions
- Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
- Trial name
- NCT07729046
- Testing
- Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Early-stage Breast Cancer
Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients
Primarily, this clinical investigation compared the efficacy of tamoxifen + aminoglutethimide vs. tamoxifen alone in terms of prognosis (overall survival) in postmenopausal patients with potentially curative, operated hormone…
- Trial name
- NCT00309491
- Testing
- Tamoxifen alone, Tamoxifen + Aminoglutethimide
- Volunteers
- 2,021 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group